A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung Cancer
Latest Information Update: 18 Dec 2025
At a glance
- Drugs JSKN 033 (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Jiangsu Alphamab Biopharmaceuticals
Most Recent Events
- 18 Dec 2025 New trial record